Efficacy and Safety of Iguratimod in the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia

NCT05302024 PHASE2 UNKNOWN

A phase 2, open-label, single-arm study to evaluate the efficacy and safety of iguratimod for the treatment of adults with steroid-resistant/relapse immune thrombocytopenia (ITP)

Details

Lead sponsor	Peking University People's Hospital
Phase	PHASE2
Status	UNKNOWN
Enrolment	100
Start date	Tue Mar 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Dec 12 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Immune Thrombocytopenia

Interventions

• Iguratimod

Countries

China